# Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

> **NCT07407465** · PHASE2 · RECRUITING · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 42 (estimated)

## Conditions studied

- Colorectal Cancer
- Colorectal Adenocarcinoma
- Rectal Adenocarcinoma
- Rectal Cancer, Adenocarcinoma
- Rectal Cancer, Metastatic
- Colon Cancer Metastatic
- Colon Cancer Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab-Deruxtecan (T-DXd)
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07407465
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2027-10-20
- **Final completion:** 2027-10-20
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407465, "Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07407465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*